Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart Plus Anlotinib Combined With SBRT in Hepatocellular Carcinoma
NCT07537777Phase 2Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Apr 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart, anlotinib in hepatocellular carcinoma (HCC), sponsored by Nanfang Hospital, Southern Medical University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
benmelstobartanlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07537777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07537777.